Bayer files marketing application for larotrectinib
Bayer has filed a marketing application in Europe seeking approval for larotrectinib as treatment for TRK fusion cancer.
Read More
Tag: Loxo
Bayer/Loxo’s larotrectinib gets speedy review in the US
Bayer/Loxo Oncology’s larotrectinib has been granted a priority review by the US Food and Drug Administration, which will consider its use to treat metastatic solid tumours carrying a certain genetic mutation.
Read More
Bayer, Loxo link in $1.55bn cancer drugs deal
Bayer and Loxo Oncology have agreed to work together on the development and commercialisation of two novel cancer therapies, in a deal potentially worth more than $1.5 billion to the latter firm.
Read More
- CERo reports encouraging early data from phase 1 trial of CER‑1236
- ENA Respiratory begins dosing in phase 2 study of INNA‑051 nasal spray
- Argo Biopharma doses first patient in phase 2b trial of BW‑20829
- Akari files new patent and advances second ADC targeting CEACAM5
- BioMed X launches kidney disease project in partnership with the government of Barbados
